利妥昔单抗注射液相关性肺炎的Meta分析(5)
[20] HAWKER K, O’CONNOR P, FREEDMAN MS, et al. Rituximab in patients with primary progressive multiple sclerosis results of a randomized double-blind placebo-controlled multicenter trial[J]. Ann Neurol, 2009, 66(4):460-471.
[21] 林桐榆, 张红雨, 黄岩,等. R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症, 2005,24(12):1421-1426.
[22] NAQIBULLAH M, SHAKER SB, BACH KS. Rituximabinduced interstitiallung disease: five case reports[J]. Eur Clin Respir J, 2014. DOI:10.3402/ecrj.v2.27178.
[23] VAN DER KOLK LE,GRILLO-L?PEZ AJ,BAARS JW, et al. Complement activation plays a key role in the side-effects of rituximab treatment[J]. Br J Haematol,2001,115(4): 807-811.
[24] BIENVENU J, CHVETZOFF R, SALLES G, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment[J]. Hematol J, 2001,2(6): 378-384.
[25] WAGNER SA, MEHTA AC, LABER DA. Rituximab-induced interstitial lung disease[J]. Am J Hematol, 2007, 82(10): 916-919.
[26] ALHO HS, MAASILTA PK, HARJULA AL, et al. Tumor necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis[J]. Transplantation,2003,76(3): 516-523.
[27] HADJINICOLAOU AV, NISAR MK, PARFREY H, et al. Non-infectious pulmonary toxicity of rituximab: a systematic review[J]. Rheumatology:Oxford, 2012,51(4): 653-662.
[28] LIU X, HONG XN, GU YJ,et al. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma[J]. Leuk Lymphoma,2008,49(9):1778- 1783.
[29] STIEGLBAUER K, PICHLER R, TOPAKIAN R. Ten- year-outcomes after rituximab formyasthenia gravis: efficacy, safety, costs of inhospital care, and impact on childbearing potential[J]. J Neurol Sci,2017. DOI:10.1016/ j.jns.2017.02.009.
[30] BESADA E,KOLDINGSNES W, NOSSENT JC. Long- term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre[J]. Rheumatology, 2013. DOI:10.1016/j.lpm.2013.02.298.
[31] VAN VOLLENHOVEN RF,EMERY P,BINGHAM CO, et al. Long-term safety of rituximab in rheumatoid arthritis:9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients[J]. Ann Rheum Dis,2013,72(9):1496-1502.
(收稿日期:2017-11-20 修回日期:2017-12-22)
(編辑:孙 冰), http://www.100md.com(白浩 孙朴 陈霞)
[21] 林桐榆, 张红雨, 黄岩,等. R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症, 2005,24(12):1421-1426.
[22] NAQIBULLAH M, SHAKER SB, BACH KS. Rituximabinduced interstitiallung disease: five case reports[J]. Eur Clin Respir J, 2014. DOI:10.3402/ecrj.v2.27178.
[23] VAN DER KOLK LE,GRILLO-L?PEZ AJ,BAARS JW, et al. Complement activation plays a key role in the side-effects of rituximab treatment[J]. Br J Haematol,2001,115(4): 807-811.
[24] BIENVENU J, CHVETZOFF R, SALLES G, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment[J]. Hematol J, 2001,2(6): 378-384.
[25] WAGNER SA, MEHTA AC, LABER DA. Rituximab-induced interstitial lung disease[J]. Am J Hematol, 2007, 82(10): 916-919.
[26] ALHO HS, MAASILTA PK, HARJULA AL, et al. Tumor necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis[J]. Transplantation,2003,76(3): 516-523.
[27] HADJINICOLAOU AV, NISAR MK, PARFREY H, et al. Non-infectious pulmonary toxicity of rituximab: a systematic review[J]. Rheumatology:Oxford, 2012,51(4): 653-662.
[28] LIU X, HONG XN, GU YJ,et al. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma[J]. Leuk Lymphoma,2008,49(9):1778- 1783.
[29] STIEGLBAUER K, PICHLER R, TOPAKIAN R. Ten- year-outcomes after rituximab formyasthenia gravis: efficacy, safety, costs of inhospital care, and impact on childbearing potential[J]. J Neurol Sci,2017. DOI:10.1016/ j.jns.2017.02.009.
[30] BESADA E,KOLDINGSNES W, NOSSENT JC. Long- term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre[J]. Rheumatology, 2013. DOI:10.1016/j.lpm.2013.02.298.
[31] VAN VOLLENHOVEN RF,EMERY P,BINGHAM CO, et al. Long-term safety of rituximab in rheumatoid arthritis:9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients[J]. Ann Rheum Dis,2013,72(9):1496-1502.
(收稿日期:2017-11-20 修回日期:2017-12-22)
(編辑:孙 冰), http://www.100md.com(白浩 孙朴 陈霞)